Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina Venetia Long, Jeffrey S. Weber, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2016
PURPOSE: To report the overall survival (OS) and clinical characteristics of BRAF inhibitor-naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase I and II study of patients with BRAF V600 mutation-positive metastatic melanoma. METHODS: BRAF inhibitor-naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group) from the non-randomly assigned (part B) and randomly assigned (part C) cohorts of the study were analyzed for progression-free and OS separately. Baseline characteristics and factors on treatment were analyzed for associations with durable responses and OS. RESULTS: For BRAF inhibitor-naive patients in the 150/2 groups (n = 78), the progression-free survival at 1, 2, and 3 years was 44%, 22%, and 18%, respectively, for part B (n = 24) and 41%, 25%, and 21%, respectively, for part C (n = 54). Median OS was 27.4 months in part B and 25 months in part C. OS at 1, 2, and 3 years was 72%, 60%, and 47%, respectively, for part B and 80%, 51%, and 38%, respectively, for part C. Prolonged survival was associated with metastases in fewer than three organ sites and lower baseline lactate dehydrogenase. OS at 3 years was 62% in patients with normal baseline lactate dehydrogenase and 63% in patients with a complete response. CONCLUSION: Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor-naive patients with BRAF V600 mutation-positive metastatic melanoma, and approximately 20% were progression free at 3 years. Durable responses occurred in patients with good prognostic features at baseline, which may be predictive.
Cited by 285 works. doi:10.1200/jco.2015.62.9345
Authors
- Georgina Venetia Long
- Jeffrey S. Weber
- Jeffrey R. Infante
- Kevin B. Kim
- ADIL I. DAUD
- Rene C. Gonzalez
- Jeffrey Alan Sosman
- Omid Hamid
- Lynn Mara Schuchter
- Jonathan Simon Cebon
- Richard F. Kefford
- Donald P. Lawrence
- Ragini Reiney Kudchadkar
- Howard A. Burris
- Gerald Steven Falchook
- Alain Patrick Algazi
- Karl D. Lewis
- Igor J. Puzanov
- Nageatte Ibrahim
- Peng Gang Sun
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma